Geneticists at Brigham and Women’s Hospital in Boston found that genome sequencing, a type of test that provides a full readout of your DNA, didn’t significantly increase health-care spending in the short term.
Sequencing for everyone? As genome sequencing gets cheaper and becomes more widely available, a major concern has been whether it will make people use more health services. Returning detailed genetic results to healthy people could make them seek out medical tests, screenings, or preventive procedures that they otherwise wouldn’t have gotten—and that they might not need.
The cost question: Among 100 patients with a known heart problem, the Boston team found that the average cost of health care over six months was $8,109 for those who had received genome sequencing and $9,670 for those who didn’t get the test. For 100 primary-care patients who were “ostensibly healthy,” average costs were slightly higher in the group that got sequenced—$3,670 versus $2,989. The researchers say those differences weren’t statistically significant, because costs varied a lot among individuals.
The caveat: The researchers only looked at health-care costs over a six-month period. That may be too short a time frame to understand how genome sequencing will affect health-care spending over the long run.
How scientists want to make you young again
Research labs are pursuing technology to “reprogram” aging bodies back to youth.
Inside the billion-dollar meeting for the mega-rich who want to live forever
Hope, hype, and self-experimentation collided at an exclusive conference for ultra-rich investors who want to extend their lives past 100. I went along for the ride.
Human brain cells transplanted into baby rats’ brains grow and form connections
When lab-grown clumps of human neurons are transplanted into newborn rats, they grow with the animals. The research raises some tricky ethical questions.
The debate over whether aging is a disease rages on
In its latest catalogue of health conditions, the World Health Organization almost equated old age with disease. Then it backed off.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.